Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Methods for concomitant administration of colchicine and macrolide antibiotics|
|Abstract:||Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.|
|Inventor(s):||Davis; Matthew W. (Erwinna, PA)|
|Assignee:||Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)|
1. A method of using colchicine to treat a gout flare in an adult human gout patient so as to reduce the occurrence of colchicine toxicity when said patient is receiving
concomitant administration of clarithromycin, said method comprising: orally administering a reduced colchicine dosage amount to the patient to treat gout flares, wherein the reduced colchicine dosage amount is about a 50% to about a 75% reduction of a
colchicine dosage amount adapted for oral administration to the gout patient to treat gout flares in the absence of concomitant administration of clarithromycin, and not repeating colchicine administration for at least three days, wherein concomitant
administration of clarithromycin is administration within 1 to 2 days of orally administering the reduced colchicine dosage amount.
2. The method of claim 1, wherein the colchicine dosage amount adapted for oral administration to the gout patient to treat gout flares in the absence of concomitant administration of clarithromycin is 1.2 mg at the first sign of a flare, followed by 0.6 mg one hour later.
3. The method of claim 2, wherein the reduced colchicine dosage amount is 0.6 mg at the first sign of a flare, followed by 0.3 mg one hour later.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.